Format

Send to

Choose Destination
J Perinatol. 2013 Mar;33(3):226-30. doi: 10.1038/jp.2012.78. Epub 2012 Jun 21.

Outcomes of extremely low birth weight infants given early high-dose erythropoietin.

Author information

1
Department of Pediatrics, Division of Neonatology, University of Washington, Seattle, WA 98195-6320, USA.

Abstract

OBJECTIVE:

To evaluate long-term outcomes of 60 extremely low birth weight (ELBW) infants treated with or without three injections of high-dose erythropoietin (Epo).

STUDY DESIGN:

A retrospective analysis of anthropometric and neurodevelopmental outcome data comparing 30 ELBW infants enrolled in a phase I/II study examining the pharmacokinetics of high-dose Epo (500, 1000 and 2500 U/kg × 3 doses) administered to 30 concurrent controls.

RESULT:

Birth characteristics and growth from 4 to 36 months were similar for untreated and Epo-treated patients. Multiple linear regression analysis of neurodevelopmental follow-up scores from 17/25 Epo-treated and 18/26 control infants identified that Epo correlated with improvement of cognitive (R=0.22, P=0.044) and motor (R=0.15, P=0.026) scores. No negative long-term effects of Epo treatment were evident.

CONCLUSION:

Retrospective analysis of the only available long-term follow-up data from ELBW infants given high-dose Epo treatment suggests that Epo treatment is safe and correlates with modest improvement of neurodevelopmental outcomes.

PMID:
22722674
PMCID:
PMC4029129
DOI:
10.1038/jp.2012.78
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center